Pillar Biosciences Launches oncoReveal® Rapid AML Panel to Support Rapid, Guideline‑Informed Genomic Insights for Acute Myeloid Leukemia
NATICK, MA — March 3, 2026 — Pillar Biosciences today announced the launch of the oncoReveal® Rapid AML Panel, a focused research-use-only (RUO) DNA next-generation sequencing (NGS) panel designed to help laboratories generate key acute myeloid leukemia (AML) genomic results more efficiently. AML is an aggressive hematologic malignancy where molecular characterization can be time-sensitive in […]
Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China
NATICK, Mass. – December 8, 2025 – (PR NEWSWIRE) – Pillar Biosciences announced today an expansion of its existing laboratory access program with AstraZeneca for NGS-based kitted liquid biopsy tumor profiling to include China. This expanded collaboration aims to deliver rapid, cost-effective, and clinically actionable genomic insights through liquid biopsy testing. By increasing the local […]
Pillar Biosciences Announces Final CMS Pricing Determination for oncoReveal® CDx
Natick, Mass. – December 1, 2025 – Pillar Biosciences, the leader in Decision Medicine™, todayannounced that the Centers for Medicare & Medicaid Services (CMS) has finalized its pricingdetermination for oncoReveal CDx. Following its preliminary decision in August 2025, CMSconfirmed a crosswalk-based payment rate of $1,352.09, effective for claims with dates of service onor after January […]
Pillar Biosciences Enables Rapid, Localized Tumor Profiling of Lymphoid Malignancies with Launch of New Kitted NGS Panel
NATICK, Mass. – November 11, 2025– (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the launch of oncoReveal® Lymphoid, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories to perform rapid tumor profiling of lymphoid malignancies. The oncoReveal Lymphoid panel interrogates 84 genes of interest, including full coding […]